HEALTHEQUITY, INC. R&D Expense

Quick Answer

HEALTHEQUITY, INC. reported R&D Expense of $262.51 million for fiscal year 2026.

HEALTHEQUITY, INC. R&D Expense — Annual History

Fiscal Year R&D Expense YoY Change
2026 $262.51M +9.6%
2025 $239.51M +9.5%
2024 $218.81M +13.2%
2023 $193.38M +22.9%
2022 $157.36M +26.1%
2021 $124.81M +60.9%
2020 $77.58M +121.3%
2019 $35.06M +28.0%
2018 $27.39M +22.4%
2017 $22.38M +32.9%
2016 $16.83M +60.3%
2015 $10.50M +47.0%
2014 $7.14M +68.9%
2013 $4.23M

Quarterly R&D Expense

Quarter Ending R&D Expense YoY QoQ
October 31, 2025 $65.92M +9.5% +1.7%
July 31, 2025 $64.80M +10.6% +5.5%
April 30, 2025 $61.44M +9.5% +2.1%
October 31, 2024 $60.19M +8.2% +2.7%
July 31, 2024 $58.58M +7.0% +4.4%
April 30, 2024 $56.09M +5.4% +0.9%
October 31, 2023 $55.61M +13.8% +1.5%
July 31, 2023 $54.77M +17.6% +3.0%
  • HEALTHEQUITY, INC. showed an increase of +9.6% in R&D Expense compared to the prior fiscal year.
  • Over the 2013–2026 period, HEALTHEQUITY, INC.’s r&d expense has grown by 6107.4% (from $4.23 million to $262.51 million).
  • The most recent figure is from HEALTHEQUITY, INC.’s fiscal year 2026 report (Form 10-K), filed with the SEC on March 17, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment